B 701

Drug Profile

B 701

Alternative Names: B701

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator BioClin Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer
  • Phase I Multiple myeloma; Solid tumours
  • Preclinical Achondroplasia

Most Recent Events

  • 22 Mar 2017 BioClin Therapeutics initiates a phase Ib/II trial in Bladder cancer (Combination therapy, Metastatic disease)
  • 01 Dec 2016 Dana Farber Cancer Institute initiates a phase I trial in Bladder cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT02925533)
  • 05 Oct 2016 Dana-Farber Cancer Institute, Merck Sharp & Dohme and BioClin Therapeutics plan a phase Ib trial for Bladder cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02925533)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top